Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.
Using Fourier transform infrared (FTIR) spectroscopy, we are aiming to create a blood test that would help identify patients who have a high likelihood of cancer. To do so we are collecting blood samples from: i) participants for whom the assessing clinician has identified a clinical need to undergo a diagnostic investigation to exclude a new brain, chest, abdominal or pelvic abnormality, where the differential diagnosis includes cancer, or ii) participants with a recent new cancer diagnosis, before surgery, chemotherapy or radiotherapy. We will use the data from anlaysed samples, and machine learning, to train an algorithm to ascertain whether a new cancer diagnosis can be accurately predicted at the time of presentation with non-specific symptoms. This would permit prioritisation for diagnostic imaging, support clinical decision making and hopefully earlier diagnosis.
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions